Last reviewed · How we verify
Nerve Injection- Nerve Stimulator
Nerve Injection- Nerve Stimulator is a Small molecule drug developed by Canadian Forces Health Services Centre Ottawa. It is currently in Phase 3 development for Peripheral nerve injury or dysfunction (specific indication not publicly detailed). Also known as: Lateral Femoral Cutaneous Nerve Block- Neurostimulation.
A nerve stimulator device that delivers electrical impulses to peripheral nerves to modulate pain signals and restore neurological function.
A nerve stimulator device that delivers electrical impulses to peripheral nerves to modulate pain signals and restore neurological function. Used for Peripheral nerve injury or dysfunction (specific indication not publicly detailed).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Nerve Injection- Nerve Stimulator |
|---|---|
| Also known as | Lateral Femoral Cutaneous Nerve Block- Neurostimulation |
| Sponsor | Canadian Forces Health Services Centre Ottawa |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Nerve stimulation works by applying controlled electrical current to targeted peripheral nerves, which can interrupt pain transmission, promote nerve regeneration, and restore motor or sensory function. This neuromodulation approach is used in Phase 3 trials for conditions involving nerve injury or dysfunction. The Canadian Forces application suggests potential military/trauma medicine use cases.
Approved indications
- Peripheral nerve injury or dysfunction (specific indication not publicly detailed)
Common side effects
- Local pain or discomfort at stimulation site
- Skin irritation or infection at electrode placement
- Unintended muscle contractions
Key clinical trials
- Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Knee Surgery (NA)
- Evaluation of Supraclavicular Brachial Plexus Blocks at Various Volumes: Impact on Optic Nerve Sheath Diameter (NA)
- Feasibility and Safety of Sciatic Nerve Paraneural Sheath Block Using a Mid-Femoral Lateral Approach (NA)
- Comparison of the Analgesic Efficacy of Erector Spinae Plane Block in Breast-Conserving Surgery Versus Serratus Anterior Block Combined With Additional Pecto-Intercostal II Block (NA)
- A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Cancer Patients (NA)
- Randomized Study of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery (NA)
- Prescription Opioids, Brain Structure, and Cognition in Older Adults With Chronic Pain (PHASE2)
- Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nerve Injection- Nerve Stimulator CI brief — competitive landscape report
- Nerve Injection- Nerve Stimulator updates RSS · CI watch RSS
- Canadian Forces Health Services Centre Ottawa portfolio CI
Frequently asked questions about Nerve Injection- Nerve Stimulator
What is Nerve Injection- Nerve Stimulator?
How does Nerve Injection- Nerve Stimulator work?
What is Nerve Injection- Nerve Stimulator used for?
Who makes Nerve Injection- Nerve Stimulator?
Is Nerve Injection- Nerve Stimulator also known as anything else?
What development phase is Nerve Injection- Nerve Stimulator in?
What are the side effects of Nerve Injection- Nerve Stimulator?
Related
- Manufacturer: Canadian Forces Health Services Centre Ottawa — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Peripheral nerve injury or dysfunction (specific indication not publicly detailed)
- Also known as: Lateral Femoral Cutaneous Nerve Block- Neurostimulation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing